COMPANIES
Resources
Blog
Special report
Health series
FT writers explore a range of healthcare issues, from technological advances to ageing and disease prevention
Principal content
Drug group acquisition boosts BTG
A full half-year of contributions from Protherics boost revenues at the biotechnology group as it looks forward to the direct marketing of two major drugs in the US next year
Roche’s Seoul offices raided in Tamiflu probe
South Korean prosecutors suspect that they Swiss drugs group illegally provided swine flu treatment to staff of HSBC and Novartis amid fears of a widespread outbreak
David Pilling: Roll up for Japan’s medical mystery tour
With a smaller slice of a shrinking domestic pie, Japanese pharmaceutical companies have had to take the fight abroad. The country’s track record outside manufacturing does not bode well, but it is too soon to dismiss the industry, writes David Pilling
ViiV vows joint venture will help fight HIV
The head of the pioneering tie-up between GlaxoSmithKline and Pfizer predicts the company can operate for at least five years without new funding from shareholders
J&J to axe 7% of jobs in global restructure
Johnson & Johnson will cut up to 7% of its 117,000 employees by 2011 as it reduces costs in an effort to weather the global downturn and increase spending on new products.
Novartis to expand Chinese research labs
Novartis plans to inject $1bn into growing its Shanghai laboratories, which would employ 1,000 scientists, and tap China’s scientific base
Lex: Takeda / Amylin
A commitment to spend hundreds of millions of dollars on developing obesity drugs is the latest move by a Japanese drugmaker to shore up growth by expanding abroad
Pfizer backs US health reform
Jeffrey Kindler, chief executive of Pfizer, expressed confidence that US healthcare reform would be approved by the end of this year, and praised the Senate finance committee’s latest draft in spite of the extra costs it would impose on his business
Shire’s drug sales offset Adderall decline
Falling sales of its now off-patent drug Adderall XR continue to weigh on the speciality pharmaceutical group, although strong growth in sales of new drugs are poised to compensate
Lex: Novo Nordisk
Bosses of most drug companies must wish they had the Danish drugmaker‘s problems. What is the secret of its success?
Related content and features
Track this Topic
News alerts
Email - create a keyword alert on the subject of this topic
Email summaries
Email - start your day with daily email briefing on this topic
RSS feeds
RSS - Track this news topic using our feeds
